Traders should view this coordinated C-suite buying as a strong vote of confidence, particularly given the use of personal funds in a micro-cap biotech with high execution risk. Monitor for upcoming clinical trial updates or financing news that may have prompted this activity.
Price Chart
Executive Summary
Multiple C-suite executives at FibroBiologics, including the CEO, CFO, and Chief Scientific Officer, collectively purchased $72,957 worth of shares in open-market transactions over the past seven days. This insider buying, concentrated among top executives, signals confidence in the company's prospects despite its small market cap of $25M.
Key Financial Metrics
Key Facts
- CEO Pete O'Heeron purchased 51,500 shares across three transactions totaling ~$19,531.
- CFO Jason Davis purchased 70,000 shares for $28,973, the largest individual buy in the cluster.
- Chief Scientific Officer Hamid Khoja bought 30,000 shares for $11,400.
- General Counsel Ruben Garcia bought 40,000 shares for $13,056.
- All transactions were open-market purchases (code P), indicating direct investment with personal capital.
- Total cluster value: $72,957, representing approximately 0.29% of the company's $25M market cap.
Financial Impact
$72,957 in aggregate insider buying over 7 days
Risk Factors
- FBLG is a micro-cap biotech with no commercial products; stock price is highly speculative.
- Insider purchases, while positive, do not guarantee near-term performance or clinical success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-FBLG-1772715668642 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers